Latest ArticlesThis article studies growth of China's listed biopharmaceutical companies. According to the Shenyin Wanguo industry classification criteria, 36 biopharmaceutical listed companies were selected, and 12 financial indicators were used to establish a growth index evaluation system. The factor analysis method was used to calculate the comprehensive growth scores of listed companies. The results show that the companies with comprehensive scores above 0.5 account for about 16.7%. The overall calculation result shows that the development space of the biopharmaceutical industry is relatively large, and the growth of China's biopharmaceutical listed companies still remain to improve. Combined with the results of factor analysis, we make recommendations, such as precise strategic planning and main business strengthening; improving talent introduction, increasing R&D investment; complying beneficial policies, and seizing development opportunities.
The relationship between the profit level and knowledge output of Chinese pharmaceutical manufacturing industry is empirically analyzed, aiming to provide reference for them to improve the profit level and knowledge output.
The relevant data of Chinese pharmaceutical manufacturing industry from 1995 to 2018 were selected, the total profit to represent the profit level and the number of valid invention patents to represent the knowledge output were used. The co-integration test was established using VAR model. Granger causality test, impulse response analysis and variance decomposition were used to explore the relationship between the two.
The profit level of Chinese pharmaceutical manufacturing industry has a long-term and significantly positive effect on knowledge output. The total profit increased by 1%, and the number of valid invention patents increased by 1.480 2%. This positive promotion effect has a certain lag, which is 2 years. Knowledge output also has a long-term significant positive promotion effect on profit level. The number of valid invention patents increased by 1%, and the total profit increased by 0.675 6%, but this promotion effect was not obvious.
This paper clarifies the usage frequency and the success rate of invalidation of various articles of patent law based on statistical analysis of the invalidation cases of drugs polymorphism patents in recent years. The paper also sumed up and sorted out some viewpoints involved in the corresponding cases, in order to provide a certain reference for pharmaceutical companies to apply for crystal patents.
As a cooperative innovation organization, the strategic alliance of industrial technology innovation is suitable for the overall innovation circumstance of pharmaceutical industry in China. By establishing the payment matrix of single game and repeated game, this paper analyzes the factors in the construction of trust mechanism of technology innovation strategic alliance in pharmaceutical industry. The results show that the information completeness, the number of games and the size of external forces are the key to the construction of trust mechanism, and the corresponding countermeasures are put forward. The results will provide some reference for the stable operation of strategic alliance.
“Guidance on Pharmaceutical Development of Paediatric Medicines” was issued by National Medical Products Administration on December 2020, aiming to encourage and facilitate the development and accessibility of paediatric medicines. This paper provides a detailed interpretation of the guidance, combined with the drafting process of the guidance and the current state of the pharmaceutical development level in China. The paper is intended to help applicants getting a better understanding of the scientific and technical requirements for pharmaceutical development of paediatric medicines.
In order to standardize the expression of the strength of Chinese patent medicine (CPM), the connotation, significance, characteristics and standard expression of CPM strengths are systematically summarized and analyzed in this paper. Furthermore, the related issues which need to be paid attention to in the implementation of “Technical Guideline for Strengths Expression of Chinese Patent Medicines” are discussed, and the following suggestions are put forward: According to the requirements of “Technical Guideline for Strengths Expression of Chinese Patent Medicine”, the theoretical amount (or marked amount) of prescription composition in each dosage should be indicated in the strengths of CPM. Drug strengths have nothing to do with the types of excipients used. It is suggested that the strengths should be reasonably expressed according to prescription composition, dosage form, usage and other characteristics of CPM. Drug strengths and capacity specification should be distinguished to facilitate the registration and management of drugs and to clarify the scope of powers of National Medical Product Administration and the Provincial Medical Product Administration. The strengths of CPM should be expressed according to the equivalent amount of decoction pieces in each dosage, which does not affect the check of capacity difference of the product.
To study the effect of arecoline on rat embryo cartilage development in vitro, so as to explore the embryonic teratogenicity of arecoline.
The embryonic limb buds of gestation day 14 timed-pregnant (GD14) rats were taken, and the forelimb buds were cultured in micromass (MM). The teratogenicity of arecoline was determined by the half-proliferation inhibitory concentration (IC50-P), the half-differentiation inhibitory concentration (IC50-D) and their ratios. The hindlimb buds were cultured in organ culture and randomly divided into five experimental groups, i.e., blank control (0 mg·mL-1 arecoline), low-dose (0.1 mg·mL-1 arecoline), middle-dose (1 mg·mL-1 arecoline), high-dose (10 mg·mL-1 arecoline), and positive control group (10 ng·mL-1 5-fluorouracil). They were cultured in vitro for 24, 72, and 120 h, respectively, and then harvested. Morphological scoring was performed under a stereo microscope, and followed by paraffin embedding, sectioning, HE staining and toluidine blue staining to observe the morphology cartilage cells. The effects of arecoline on the expression of bone morphogenetic protein 2 (BMP-2) in each group were studied by immunohistochemistry.
In MM model, according to the ECVAM prediction model, it was determined that arecoline was a developmental toxic chemical and a non-specific weak teratogen. In the limb bud organ model, 1 mg·mL-1 (medium dose) and above concentrations of can cause developmental toxicity arecoline to limb bud organs. Arecoline at 10 mg·mL-1 (high dose) can produce significant toxicity after 24 h of administration. The developmental status of each dose group has a significant measurement correlation after 72 h of culture. It can be seen from the pathological section results that arecoline further affected the proliferation and differentiation of proliferating chondrocytes and hypertrophic chondrocytes, thereby affecting the development of limb buds, palms and limbs. In the immunohistochemical analysis, the expression intensity of BMP-2 was related to the dose of arecoline. The larger the dose of arecoline used, the lower degree of positive expression obtained, reflecting the slowdown of chondrocyte proliferation and differentiation.
Arecoline at concentration over 1 mg·mL-1 inhibited the growth of rat embryonic limb buds and cartilage development in vitro. It can be preliminarily believed that arecoline has weak teratogenicity on embryonic development, and arecoline affected the expression of BMP-2 to inhibit the proliferation and differentiation of chondrocytes directly or indirectly.
Opioid analgesics are still irreplaceable for the treatment of moderate to severe pain, but the usage is limited because of their dependence and other adverse reactions. There is an urgent need for a new generation of efficient and safe opioid analgesics. At present, many studies on the interaction between μ and δ opioid receptors have been reported, and the existence of μ/δ dimer also provides a molecular basis for the receptor interaction. The design of molecules with double activation effect on μ and δ types is the new development direction of opioid drugs with strong analgesic effect and little or weak adverse reactions. In this paper, the research progress of μ/δ dual agonists in recent years is reviewed according to the classification of design strategy of μ/δ dual agonist.
Multitargeted tyrosine kinase inhibitors have shown significant therapeutic effects in antitumor therapy. As one of the most common side effects, hyperlipidemia has drawn increasing attentions. Five similar drugs were selected in this review in order to investigate the relationship between hyperlipidemia and therapeutic outcomes of multitargeted tyrosine kinase inhibitors and further illustrate the underlying mechanisms. The reported occurrences of hyperlipidemia in patients treated with them were summarized and possible mechanisms of treatment-induced hyperlipidemia were discussed, which would benefit for searching optimal targeted patients and designing rational therapeutic schedules to improve the survival benefits of patients with carcinomas.
Janus kinases (JAKs) are a class of non-receptor tyrosine kinases. In the past two decades, small-molecule Janus kinases inhibitors have gradually entered the public vision and received extensive attention from researchers. JAKs can regulate cell proliferation, differentiation, apoptosis, angiogenesis and immunity through JAK-STAT signal pathway formed by Janus kinases and their downstream signal transducers and activators of transcription. The inhibitors of JAKs can be used for prevention and treatment of autoimmune diseases, inflammatory reactions and malignant tumors. At present, nearly ten small-molecule Janus kinases inhibitors have been approved for marketing, and some others are in clinical research stage. This review summarizes the structure of Janus kinase, JAK-STAT signaling pathway, research and development progress and clinical application of JAKs inhibitors in recent years, providing useful reference for the further research and development of this class of inhibitors.
No. 86 Xueyuan South Road, Haidian District, Beijing
010-62662699(Operation and Technical Support)
qkjq@cast.org.cn
Copyright © 2025 China Association for Science and Technology. All rights reserved. For all open access content, the relevant licensing terms apply.
Sponsored by the Office of the Leading Group for Cybersecurity and Informatization of CAST, and supported by Science and Technology Review Publishing House
